Clarify announced the launch of Clarify Trials today. It is a real-world evidence-based software product that empowers life sciences companies to improve the recruitment of diverse and underrepresented patient populations.
This cloud software accelerates clinical trial recruitment within underrepresented communities and provides over 400 social determinants of health (SDoH) insights to identify research sites and investigators with the best opportunity to enroll diverse patients and assess physician referral patterns to support coordinated outreach within underserved populations. As life sciences companies and clinical research organizations (CROs) navigate the FDA’s 2020 guidance to enhance diversity in clinical trials, this solution enables them to proactively reduce health disparities without unnecessary trial delays, budget overruns, or protocol amendments.
Clarify Trials’ analytics draws upon a dataset that includes patient-level SDoH data across an extensive set of factors, such as gender, race, ethnicity, income level, transportation access, housing stability, education level and health literacy. These data are linked to government and commercial claims, clinical, prescription and dispensing data, covering over 300 million patient lives. With a window into how medical care and SDoH interconnect to influence each patient’s journey, life sciences companies can evaluate health disparities within distinct patient cohorts and recruit a trial population that best reflects their therapy’s future patient population.
“The ongoing pandemic has cast a light on long-standing, unfortunate truths about disparities within healthcare, including a lack of diversity and inclusion in clinical trials,” said Kenneth Park, MD, SVP and GM of Life Sciences, Clarify Health. “Clarify Trials addresses an unmet need in the market by looking at trial recruitment with a diversity lens. It goes beyond assessing the historical performance of research sites and investigators by precisely determining their ability to recruit underrepresented patients.”
“Greater clinical trial diversity has an important role to play in tackling undeniable disparities in healthcare,” said Jean Drouin, MD, CEO, Clarify Health. “Clarify’s patient journey analytics deliver socio-behavioral insights to ensure the people most in need are included in clinical research, accurately diagnosed and prescribed the right therapy.”
Clarify’s life sciences software is acclaimed by Frost & Sullivan for being the most innovative RWE solution in the life sciences industry. The research firm cited that Clarify “is in a prime position to lead RWE IT solutions in life sciences.” To learn more about Clarify Trials, visit https://clarifyhealth.com/clarify-trials.
Clarify will be at SCOPE Summit in Orlando, FL, February 7-10. Schedule a meeting to learn how Clarify can boost diversity in clinical trials by visiting: https://calendly.com/clarify-health-scope/scope-summit.
About Clarify Trials
Clarify Trials is a cloud analytics software that accelerates the recruitment of underrepresented patient populations for clinical trials. Sponsors and clinical research organizations are able to identify and select research sites and investigators with the best opportunity to recruit diverse patients. Clarify Trials delivers 400+ social determinants of health (SDoH) insights across an extensive set of factors, such as gender, race, ethnicity, income level, transportation access, housing stability, education level and health literacy. It also allows clinical trial teams to identify and engage with physicians treating diverse communities through insights into primary care and specialist referral patterns—the same insights used by leading health systems to optimize their provider networks.
